OBJECTIVE： To study related factors of ACEI/ARB drugs in hypertension patients with coronary heart disease. METHODS： Six hundred hypertension patients with coronary heart disease were selected from a hospital during Jan. 2012-Jan. 2015， 310 patients receiving ACEI/ARB drugs were included in observation group， and 290 patients not receiving these drugs were included in control group. General information and lab indexes of 2 groups were collected and analyzed. RESULTS： There were statistical significances in ambulatory arterial stiffness indexes [（0.57±0.13），（0.40±0.11）]， 24 h average systolic blood pressure [（146.42±11.24）mmHg， （132.31±9.85）mmHg]， 24 h average diastolic blood pressure [（78.14±9.21）mmHg， （82.79±8.33）mmHg]， 24 h ambulatory pulse pressure [（64.89±13.57）mmHg，（53.54±9.78）mmHg]， drinking rate （58.71％， 28.28％）， moderate intensity rate （31.29％， 65.17％）， BMI[（33.28±2.07）kg/m2，（23.17±2.86）kg/m2]， LVEF [（35.65±11.42）％， （48.01±12.45）％]， dyslipidemia rate （66.77％， 30.34％）， myocardial infarction rate （68.39％， 39.66％）， revascularization rate （69.68％， 33.10％） and duration of coronary heart disease between 2 groups （P＜0.05）. The duration of coronary heart disease， dyslipidemia， myocardial infarction， revascularization were included in multivariate Logistic regression analysis， with statistical significance （P＜0.05）. CONCLUSIONS： The application of ACEI/ARB drugs in hypertension patients complicated with coronary heart disease is influenced by many factors； dyslipidemia， myocardial infarction and revascularization are positive independent influential factors of ACEI/ARB drug use in the treatment， but drug use rate will decline with the duration increase.